TMCnet News

Cross-Border Impact Ventures Announces US$58 Million First Close of Women's and Children's Health Technology Fund II
[August 06, 2026]

Cross-Border Impact Ventures Announces US$58 Million First Close of Women's and Children's Health Technology Fund II


Cross-Border Impact Ventures (CBIV) today announced the first close of its second fund, the Women's and Children's Health Technology Fund II, securing US$58 million toward a target fund size of US$125 million. The new fund has attracted commitments from both returning and new institutional investors, reflecting continued confidence in CBIV's investment strategy, team, and track record. LPs in the new fund include returning investors who doubled down, including KfW on behalf of German Federal Ministry for Economic Cooperation and Development (BMZ), the Skoll Foundation with its OCIO - Capricorn Investment Group, Ceniarth, Equality Fund with its OCIO - RockCreek Group, Wire Group, and several family offices and high-net-worth individuals, among others. CBIV expects to complete the final close of Fund II in 2027.

CBIV invests in companies developing technologies that address conditions affecting women and children specifically, differently or disproportionately at the Series A or B stage. CBIV's inaugural US$90.3 million Fund I invested in 11 technology companies spanning maternal and fetal health, neonatal care, cardiovascular disease, oncology, respiratory health, reproductive health and gut health. Fund I had a successful strategic exit and helped the portfolio reach more than 356,000 women and children across 32 countries.

Fund II represents a disciplined evolution of CBIV's original investment thesis while maintaining its focus on early-growth-stage deep tech companies commercializing medical devices, diagnostics, therapeutics, and AI-enabled digital health technologies with the potential to generate strong financial returns alongside measurable health outcomes. CBIV has also introduced an integrated climate lens into its investment process for Fund II, has further strengthened its impact approach, and may invest earlier in some high-potential companies.


Investing at the Intersection of Innovation, Returns, and Impact
Fund II comes as women's and children's health emerges as one of healthcare's most significant investment opportunities. CBIV estimates that its sectors of interest represent a US$625 billion market today, projected to grow to US$1.1 trillion by 2035, driven by advances in AI, diagnostics, medical devices and precision medicine, alongside growing recognition that addressing longstanding gaps in women's and children's healthcare represents both a societal imperative and a significant commercial opportunity.

About Cross-Border Impact Ventures
Cross-Border Impact Ventures (CBIV) is an impact venture capital firm on a mission to revolutionize venture investing in health technology. CBIV invests in early-growth-stage health technology companies commercializing medical devices, diagnostic tools, therapeutics, and digital health solutions. Its investment strategy focuses on companies that use advanced technologies such as Artificial Intelligence (AI) and Machine Learning (ML) to improve outcomes for health conditions that specifically, disproportionately, or differently impact women and children. The firm is driven by the belief that good health should not be restricted by gender, age, race, wealth, or borders and seeks to expand access to the world-class technologies offered by its portfolio companies, inclusively and globally. For additional information, visit crossborder.ventures.


[ Back To TMCnet.com's Homepage ]